Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link. All three major indices are trading down today with the Dow Jones Industrial Average ( ^DJI) trading down 42 points (-0.3%) at 15,847 as of Thursday, Dec. 5, 2013, 11:45 AM ET. The NYSE advances/declines ratio sits at 971 issues advancing vs. 1,916 declining with 131 unchanged. The Health Care sector currently sits down 0.3% versus the S&P 500, which is down 0.4%. Top gainers within the sector include Fresenius Medical Care AG & Co. KGaA ( FMS), up 2.0%, and Covidien ( COV), up 0.7%. On the negative front, top decliners within the sector include Cigna ( CI), down 1.4%, HCA Holdings ( HCA), down 1.0%, UnitedHealth Group ( UNH), down 0.9%, WellPoint ( WLP), down 0.7% and Biogen Idec ( BIIB), down 0.5%. TheStreet would like to highlight 3 stocks pushing the sector higher today: 3. Hospira ( HSP) is one of the companies pushing the Health Care sector higher today. As of noon trading, Hospira is up $1.10 (2.7%) to $41.31 on heavy volume. Thus far, 1.3 million shares of Hospira exchanged hands as compared to its average daily volume of 765,400 shares. The stock has ranged in price between $39.85-$42.43 after having opened the day at $39.85 as compared to the previous trading day's close of $40.21. Hospira, Inc. provides injectable drugs and infusion technologies to develop, manufacture, distribute, and markets products worldwide. Hospira has a market cap of $6.6 billion and is part of the drugs industry. Shares are up 28.7% year to date as of the close of trading on Wednesday. Currently there are no analysts that rate Hospira a buy, 1 analyst rates it a sell, and 7 rate it a hold. TheStreet Ratings rates Hospira as a hold. The company's strengths can be seen in multiple areas, such as its compelling growth in net income, revenue growth and largely solid financial position with reasonable debt levels by most measures. However, as a counter to these strengths, we find that we feel that the company's cash flow from its operations has been weak overall. Get the full Hospira Ratings Report now. 3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.